In a public decision dated August 8, 2024, Justice Furlanetto of the Federal Court found Boehringer Ingelheim’s Canadian Patent No. 2,591,083 (the 083 patent) valid and infringed by JAMP in an action ...
Please provide your email address to receive an email when new articles are posted on . Increased body surface area lowered the likelihood for nintedanib dose reduction/discontinuation among patients ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and pirfenidone. The FIBRONEER trials support nerandomilast's efficacy in reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback